XML 42 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue from Contracts with Customers (Tables)
6 Months Ended
Jun. 30, 2024
Revenue from Contracts with Customers  
Summary of product revenue provision and allowance

The following tables summarize activity in each of the Company’s product revenue provision and allowance categories for the six months ended June 30, 2024 and 2023:

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance as of December 31, 2023

$

149,826

$

77,505

$

20,917

Provision related to current period sales

197,088

19,937

79,615

Changes in estimate related to prior period sales

325

2,406

(79)

Credits/payments made

(192,073)

(18,806)

(78,578)

Balance as of June 30, 2024

$

155,166

$

81,042

$

21,875

    

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance as of December 31, 2022

$

156,937

$

73,554

$

22,058

Provision related to current period sales

211,709

20,958

73,382

Changes in estimate related to prior period sales

(1,623)

1,230

593

Credits/payments made

(227,167)

(22,509)

(73,076)

Balance as of June 30, 2023

$

139,856

$

73,233

$

22,957

(1)Provisions for rebates and incentives include managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets.
(2)Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets.
(3)Provisions for trade allowances and chargebacks include fees for distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s Condensed Consolidated Balance Sheets.
Schedule of disaggregation of revenue

Three Months Ended June 30,

Six Months Ended June 30,

2024

2023

2024

2023

Belbuca

$

52,198

$

43,136

$

102,861

$

87,348

Xtampza ER

44,571

    

41,245

90,384

89,114

Nucynta IR

25,203

28,158

51,163

56,057

Nucynta ER

19,272

19,171

38,458

40,307

Symproic

4,032

3,836

7,333

7,487

Total product revenues, net

$

145,276

$

135,546

$

290,199

$

280,313